Delivering on our Commitments to Canadians

Delivering on our Commitments to Canadians

What sets us apart? Bristol-Myers Squibb has a unique BioPharma strategy of growth through innovation that combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility of a forward-thinking successful biotech company.

How We Meet our Commitments Bristol-Myers Squibb is a global biopharmaceutical company firmly committed to a single Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our Commitment We promise to act on our belief that the priceless ingredient of every product is the integrity of its maker. We operate with effective governance and high standards of ethical behaviour. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs. We take our commitment to economic, social and environmental sustainability seriously, and extend this expectation to our partners and suppliers. The values and principles espoused in our Mission and Commitment, and applied in our Standards of Business Conduct and Ethics, guide every action we take and every decision we make in the course of our business practices. In the past decade, Bristol Myers Squibb has introduced ten important new products for Canadians, including both biologics and small molecules. Many more innovative potential new medicines, focused on areas of serious unmet medical needs, are being studied in preclinical and clinical trials worldwide and are advancing through our robust R&D pipeline. Our BioPharma Strategy Bristol-Myers Squibb has a unique BioPharma strategy which combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility of a successful biotech company. In the past decade, Bristol-Myers Squibb has launched ten new products for Canadians in need, including medicines for cancer, heart disease, diabetes, HIV/AIDS, rheumatoid arthritis, hepatitis B and psychiatric disorders. Most of these were discovered in our laboratories. More innovative medicines are on the way to help patients prevail over serious diseases, thanks to the company s well defined discovery strategy and robust pipeline. All are focused on addressing serious unmet medical needs around the world. To enhance the value of the Bristol-Myers Squibb pipeline, the company is partnering with other large companies in a manner similar to biotech companies to extend our reach to Canadian physicians and patients. Brochure 2010 1

Our Commitment to the Most Effective & Vital Research These are exciting times to be in research and development. Bristol-Myers Squibb is recognized as a leader in this area. Bristol-Myers Squibb is a new kind of enterprise: a nextgeneration BioPharma company. We are different. Our BioPharma strategy is based on three pillars: 1. Innovation not only in our pipeline and products, but in everything we do 2. Selective Integration taking what we do best internally and combining that with the best external processes, people and products 3. Continuous Improvement to continually become more productive, efficient and effective across our business We Embrace the Agile Leading-Edge Biotechnology Spirit We have a passion for innovative science, a focus on serious diseases with significant unmet medical needs. We are creating a more entrepreneurial culture, one that values individual contributions while fostering collaborative and productive teamwork, both within the company and with our external partners. We Honour and Preserve our Traditional Pharmaceutical Roots Our pharmaceutical roots go back over 125 years to the company s founding in Clinton, New York, in 1887. They can be seen in our financial strength and scale; our expertise in process engineering, clinical development, the regulatory process and in integrating capabilities across multiple disease areas; and our traditional focus on advances in small-molecule chemistry that have led to truly innovative medicines over many years. The Bristol-Myers Squibb pipeline of new medicines continues to advance. In 2011, in addition to new products being approved, 14 investigational new compounds entered preclinical development and four transitioned to mid-stage clinical testing. Approximately one third of all compounds in development are biologic medicines. Our String of Pearls We know we can t do everything ourselves. Since 2007, we have been enhancing our internal capabilities to meet our commitment to patients through strategic partnerships, alliances and acquisitions what we call our String of Pearls. These pearls have been pivotal to the company s continued progress in biologics, development of targeted small molecules and other next generation platforms. In 2011, Yervoy (ipilimumab) became the first product from the String of Pearls strategy to receive regulatory approval in the U.S. (2012 in Canada). Our full array of partnership pearls to date encompasses many of our key disease areas, including cancer, cardiovascular disease, immunology, neuroscience and virology. At the same time, we have partnered with other large companies in a manner similar to biotechnology companies to extend our commercial capabilities. Alliances with AstraZeneca and Pfizer are examples of this biotech-like approach.

Our Pipeline We focus our biopharmaceutical research and development efforts in six core therapeutic areas cancer, cardiovascular, immunology, metabolics, neurosciences and virology concentrating on conditions with significant unmet medical needs. Our pipeline is robust and rich with innovative possibilities. We have more than 60 compounds in active development. The Bristol-Myers Squibb pipeline of new medicines continues to be one of the best in the industry. About a third of the compounds in development are biologics. THE BRISTOL-MYERS SQUIBB PIPELINE BY DISEASE AREA As of December 31, 2012 Cancer Cardiovascular 8 3 3 Immunology (including rheumatoid arthritis & solid organ transplant rejection) 7 1 Metabolics (including diabetes & obesity) 10 2 Neurosciences (including psychiatric disorders & Alzheimer s disease) 4 1 5 Virology (including HIV/AIDS & hepatitis) 5 7 3 4 TOTAL 41 7 15 Each investigational compound is represented in the chart as a bar Exploratory Development compounds are investigational drugs that are post discovery through Phase II. Full Development compounds are investigational drugs that are in late-stage clinical development, or have been submitted to regulatory agencies for approval. Marketed Product Development compounds have been approved in at least one major market and are among approved medicines that are under further study to determine the safety and efficacy of potential additional indications and formulations. Brochure 2010 3

Delivering on our Commitments to Canadians Bristol-Myers Squibb in CANADA The Bristol-Myers Squibb roots in Canada go back almost 90 years to the incorporation in 1925 of E.R. Squibb & Sons of Canada Limited, with headquarters in Toronto. In 1952, the company moved to new Canadian headquarters in the Montreal suburb of Ville St-Laurent, Quebec, where it remained for the next 57 years. In 1989 the company expanded its activities through the merger with Bristol-Myers Company. In 2009, Bristol-Myers Squibb Canada moved to its current headquarters in the Ville St-Laurent Technoparc. Over the years, Bristol-Myers Squibb has become a trusted partner to Canadian patients and healthcare providers, introducing many innovative therapies, including the first cancer treatments more than 40 years ago. The Bristol-Myers Squibb presence in Canada will deepen as we bring more innovative new treatments for Canadians. We have been increasing our research and development investments as well as our involvement with the medical community, patient groups and patients, and the communities in which we operate. INVESTMENTS in CANADA From 2007 to 2011, Bristol-Myers Squibb invested almost $300 million in R&D in Canada. In 2011, Bristol-Myers Squibb R&D investments were close to $50 million in Canada. 37% in preclinical research ($18 million). 63% in clinical research ($31 million). In 2011, the Bristol-Myers Squibb R&D-to-sales ratio in Canada was 12.4% when adjusted for revenues from joint-venture partners, well above the industry average. We have provided more than $4.4 million in grants and donations in 2011 to stakeholders and health organizations across Canada. INVESTINg in People in CANADA The total number of Bristol-Myers Squibb employees in Canada is close to 350.

Our Commitment to Canadian R&D Bristol-Myers Squibb is committed to an extensive program of research and development in Canada, with investments in clinical studies to develop new medicines and other projects at centres across Canada. Canadian R&D by the numbers: Number of molecules being examined in different therapeutic areas: 25 Number of clinical studies conducted in Canada in 2011: 79 Number of Canadian sites for clinical studies: 384 Number of Canadian patients enrolled: 2,377 A Cancer R&D Partnership One exciting example of our R&D in Canada is our partnership with the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal. The research collaboration supports two oncology projects aimed at designing new, more effective cancer treatments based on a novel approach and technology developed at IRIC for targeting disease pathways. Bristol-Myers Squibb will develop the new treatments that result, with IRIC receiving milestone and royalty payments. Clinical Studies by Therapeutic Area 5% 19% 51% 2% 14% 9% STUDIES Neurosciences...4 Oncology...40 Cardiovascular... 7 Immunology...11 Metabolics... 2 Anti-Infectives...15 Brochure 2010 5

Helping Patients Prevail with Innovative Treatments Our Commitment to our Patients and Customers At Bristol-Myers Squibb, we are committed to scientific excellence. We are investing in biopharmaceutical research and development to provide innovative, high-quality medicines that address the unmet medical needs of patients with serious diseases. We apply scientific rigor to produce medicines that improve patients lives and provide clinical and economic benefit. The Power of Partnerships Bristol-Myers Squibb believes in the power of partnerships to create not just business success, but success for patients. That s why a key part of our strategy is partnering with other biotech and pharmaceutical companies to work together to bring our new medicines to Canadians. This allows us and each of our partners to focus our energies on what we do best, while together we create even greater benefit for Canadian patients. New Bristol-Myers Squibb medicines TO help Canadians PREVAIL OVER serious DISEASES HIV/AIds Metastatic colorectal cancer (second line) (1) Hepatitis B Chronic myeloid leukemia (CML) with resistance/ intolerance to prior therapy Moderate to severe rheumatoid arthritis (second line) Juvenile rheumatoid arthritis HIV/AIds (2) 2003 2005 2006 2007 2008 1 In partnership with Eli Lilly 2 In partnership with Gilead 3 In partnership with AstraZeneca 4 In partnership with Pfizer

Delivering on our commitment to Canadians Head and neck cancer (1) Metastatic colorectal cancer (third line in KRAS wild-type tumours) Schizophrenia in adolescents Melanoma (second line) Type 2 diabetes (add-on to metformin or a sulfonylurea) (3) Rheumatoid arthritis (first line, in combination with methotrexate) (1) Anticoagulant for venous thromboembolism (VTE) prevention (4) Bipolar I disorder in adolescents Type 2 diabetes (add-on to insulin) Schizophrenia and bipolar I disorder in adults 2009 2010 Newly diagnosed chronic phase CML 2011 2012 Prevention of stroke and systemic embolism in patients with atrial fibrillation (4) This brochure is not intended to promote use of any Bristol-Myers Squibb Canada medicines. For more information about these and other company products, please visit www.bmscanada.ca. Brochure 2010 7

Legacy and Leadership in Major Disease Areas Bristol-Myers Squibb medicines are making a huge difference to patients lives in many disease areas. Our legacy and leadership has been particularly strong in tackling cancer, cardiovascular and metabolic diseases, and in fighting immunological disorders such as HIV/AIDS. The legacy, and the leadership, continues. A Half-Century Commitment to Canadians with Cancer Bristol-Myers Squibb provided its first anti-cancer medication, Cytoxan (cyclophosphamide), for patients more than four decades ago a medicine still prescribed and making a difference to cancer patients today. Now, with an oncology portfolio of approved medicines and innovative compounds in development, Bristol-Myers Squibb is poised for global leadership in this vital treatment area. Since 2005, Bristol-Myers Squibb has launched three new cancer medications, acquired two biotech companies with leading-edge oncology programs, formed alliances with key scientific partners through its String of Pearls strategy, and built a more robust pipeline of early and late-stage anti-cancer compounds. The company s oncology R&D pipeline of about 15 compounds in development represents a wide range of treatment platforms, including traditional cytotoxics as well as biologics, immunotherapies and other novel and targeted approaches. We are helping cancer patients prevail. Helping the Fight Against Society s Major Health Challenges As we face an aging population, major health challenges for the broad community are cardiovascular disease and diabetes, both often the result of the epidemic of obesity in our North American society. Bristol-Myers Squibb is committed to providing solutions for these diseases and has a history of having done so. Cardiovascular disease and diabetes are both very complex illnesses that generally impact patients over a long period of time and in different ways. Over the last 35 years, Bristol-Myers Squibb researchers have contributed to our knowledge of, and ability to treat, these diseases by developing innovative new therapies. These include medicines to lower blood pressure, control cholesterol levels and prevent blood clots all contributing to the great advances in extending peoples lives. Our medicines have also had a great impact on treating type 2 diabetes, contributing significantly to helping patients prevail over this illness which, if not properly controlled, can lead to drastic consequences. In Canada, given the long wait times for diabetes patients to see endocrinologists, we created the Diabetes Community of Practice Program which pairs participating general practice physicians with local endocrinologist mentors. The result primary care physicians feel more comfortable and empowered to treat diabetes, providing patients with faster access to needed care. The Promise of Immuno-oncology Among the most promising areas of cancer research is immuno-oncology, a new treatment approach that seeks to harness the body s own immune system to fight tumour cells. Bristol-Myers Squibb began work in this field in the mid-1990s and is now in the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers. In February 2012, the immunotherapy Yervoy (ipilimumab) was approved by Health Canada for the treatment of metastatic melanoma, the most serious type of skin cancer.

Extending Lives for People with HIV/AIDS Before the mid-1990s, a diagnosis of infection with human immune-deficiency virus (HIV) was effectively a death sentence, leading inevitably to acquired immune deficiency syndrome (AIDS). Bristol-Myers Squibb was one of the leaders in transforming this dismal situation by developing several important treatments which led to the introduction of highly active antiretroviral therapy (HAART) in 1996-97. HAART reduced the mortality rate by about two-thirds within three years. Further advances, such as the Bristol-Myers Squibb medications Sustiva (efavirenz) and Reyataz (atazanavir), have transformed HIV infection into a generally manageable chronic illness. In Canada, deaths from AIDS peaked at 1,501 in 1995. Ten years later, in 2005, the number of Canadian deaths from AIDS had dropped to 59, a decrease of more than 95%. We are proud of the important role we have played in this important story of medical triumph over a killer infection, one of the major medical success stories of recent years. Brochure 2010 9

Meeting our Commitments around the World Bristol-Myers Squibb recognizes its duty to be a responsible corporate citizen around the world. As a leading BioPharma company, we are particularly interested in addressing unmet medical needs, eliminating health disparities and barriers to care; improving the quality of science and technology education in schools; and delivering essential services to the most vulnerable, wherever they are. This includes acting quickly in times of need following natural disasters such as the 2011 earthquake and tsunami in Japan and the 2010 earthquake in Haiti. For Japan, Bristol-Myers Squibb contributed $500,000 to Save the Children for Japan relief efforts and matched employee contributions worldwide to various charities supporting the relief effort. For Haiti, Bristol-Myers Squibb responded with both cash and product donations. In 2011, the company made product donations valued at more than $488 million (wholesale value) in response to disasters and ongoing humanitarian needs. The Bristol-Myers Squibb Secure the Future program was the first and remains the largest corporate philanthropic commitment to fighting HIV/AIDS in Africa. Since 1999, Bristol-Myers Squibb and the Bristol Myers Squibb Foundation have committed more than $165 million to develop and replicate innovative and sustainable solutions for vulnerable populations who are infected with or affected by HIV/AIDS in sub Saharan Africa. Recently it has evolved to include a collaboration with the World Health Organization to use the lessons learned in the fight against HIV to scale up community-based activities to fight tuberculosis and joint tuberculosis/ HIV infection. The Bristol-Myers Squibb Foundation has four other areas of strategic focus to improve health and promote sustainability in our global communities: Type 2 diabetes, where our efforts are empowering patients to manage their disease and mobilizing communities to make the health choice the easy choice; Hepatitis in Asia, where millions are chronically infected with hepatitis B and C; Cancer in central and eastern Europe, where access to cancer education, treatment, prevention and care is especially needed; and Mental Health and Well-Being in the U.S., focusing at the community level on two vulnerable groups: military members, veterans and their families as well as people in the criminal justice system who have mental illness.

Meeting our Commitment to Canadian Communities We believe it is important to lend a helping hand to the communities in which we live and work. We are proud to mobilize our talent and resources to benefit organizations that work every day to help Canadians in many different ways. In 2011, Bristol-Myers Squibb Canada contributed $4.4 million to various charitable causes and health organizations across Canada. We promote conscientious citizenship that improves health and promotes sustainability in our communities. Our giving is administered through a variety of programs, each with its own focus and application procedure. Please visit www.bmscanada.ca for more information. Brochure 2010 11

Medicines: Our Best Investment in Healthcare Along with encouraging Canadians to embrace healthy lifestyle habits, medicines are the best investments we can make in our healthcare system. In most cases, medicines are the easiest, least invasive and most cost-effective way to treat and prevent diseases. Recent new advances, like treating gastric ulcers, prevent far more costly, invasive and dangerous procedures such as surgery. In almost any healthcare situation, the first choice of the patient is drug therapy. In many cases, their wish comes true, and at an amazingly low cost, considering the alternatives. References 1. Canadian Institute for Health Information (CIHI), National Health Expenditure Trends 1975 to 2012, October 2012, p. 21 at www.cihi.ca 2. Skinner BJ and Rovere M, The Misguided War against Medicines 2010, The Fraser Institute, October 2010, p. vi at www.fraserinstitute.org 3. Patented Medicine Prices Review Board, 2011 Annual Report, May 2012, p. 19 at www.pmprb-cepmb.gc.ca Key numbers about drugs and the Canadian healthcare system: Percent of total Canadian healthcare costs (2010) spent on drugs including patented brand-name, generic and non-prescription (over-the-counter) drugs, pharmacy fees, distribution, etc.: 15.9% 1 Percent of provincial government health budgets spent on patented prescription drugs (2009): 5.5% 2 Percent of total Canadian healthcare costs (2009) spent on hospitals and other institutions: 39.5% 1 Savings in other parts of the healthcare system for every dollar spent on new drugs: $3.00 to $7.95 2 Highest annual percentage increase in overall prices of patented drugs in Canada annually for the past 20 years: 0.7 percent (with no increase or declines in 11 of those years) 3 We do not yet have effective drug therapies for every condition. That is why companies such as Bristol-Myers Squibb continue to search for new medicines that will keep providing benefits to the Canadian healthcare system and will help patients prevail.

Bristol-Myers Squibb Canada, 2344 Alfred Nobel Boulevard, Suite 300, Montreal, Quebec H4S 0A4 www.bmscanada.ca General information: 1 800 267-1088 or 514 333-3200 Rx&D, Canada s Research-Based Pharmaceutical Companies www.canadapharma.org Proud member of BIOTECanada www.biotech.ca The Bristol-Myers Squibb Commitment to the Environment We encourage the preservation of natural resources and strive to minimize the environmental impact of our operations and products. Printed in Canada on paper that is sourced from FSC certified forests. 2012, Bristol-Myers Squibb Canada Co. 1316356